Immuneering (IMRX) Competitors $1.25 -0.04 (-3.10%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. YMAB, NVCT, OCGN, LFCR, GOSS, CRGX, PLX, HUMA, ZYBT, and CDTXShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Ocugen (OCGN), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), CARGO Therapeutics (CRGX), Protalix BioTherapeutics (PLX), Humacyte (HUMA), Zhengye Biotechnology (ZYBT), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Y-mAbs Therapeutics Nuvectis Pharma Ocugen Lifecore Biomedical Gossamer Bio CARGO Therapeutics Protalix BioTherapeutics Humacyte Zhengye Biotechnology Cidara Therapeutics Y-mAbs Therapeutics (NASDAQ:YMAB) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk. Does the MarketBeat Community believe in YMAB or IMRX? Y-mAbs Therapeutics received 102 more outperform votes than Immuneering when rated by MarketBeat users. However, 69.23% of users gave Immuneering an outperform vote while only 63.30% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformY-mAbs TherapeuticsOutperform Votes13863.30% Underperform Votes8036.70% ImmuneeringOutperform Votes3669.23% Underperform Votes1630.77% Does the media favor YMAB or IMRX? In the previous week, Y-mAbs Therapeutics had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.96 beat Y-mAbs Therapeutics' score of 0.79 indicating that Immuneering is being referred to more favorably in the news media. Company Overall Sentiment Y-mAbs Therapeutics Positive Immuneering Positive Which has more risk and volatility, YMAB or IMRX? Y-mAbs Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Do institutionals & insiders hold more shares of YMAB or IMRX? 70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 22.5% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, YMAB or IMRX? Y-mAbs Therapeutics has higher revenue and earnings than Immuneering. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$87.69M2.34-$21.43M-$0.67-6.78Immuneering$320K140.18-$53.47M-$2.03-0.62 Do analysts rate YMAB or IMRX? Y-mAbs Therapeutics presently has a consensus target price of $18.30, indicating a potential upside of 303.08%. Immuneering has a consensus target price of $12.50, indicating a potential upside of 900.00%. Given Immuneering's higher probable upside, analysts clearly believe Immuneering is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91Immuneering 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is YMAB or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Y-mAbs Therapeutics' return on equity of -24.61% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-28.22% -24.61% -18.49% Immuneering N/A -79.19%-69.08% SummaryY-mAbs Therapeutics beats Immuneering on 12 of the 19 factors compared between the two stocks. Remove Ads Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.86M$6.27B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.636.6921.6917.68Price / Sales140.18222.71373.9692.89Price / CashN/A65.6738.1534.64Price / Book0.405.776.363.94Net Income-$53.47M$142.01M$3.20B$247.45M7 Day Performance0.81%5.79%3.96%3.17%1 Month Performance-25.60%-15.47%-10.34%-8.53%1 Year Performance-32.80%-10.99%10.38%0.32% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.6246 of 5 stars$1.25-3.1%$12.50+900.0%-32.1%$44.86M$320,000.00-0.6360Short Interest ↓Gap DownYMABY-mAbs Therapeutics3.5514 of 5 stars$4.28-5.7%$18.30+327.6%-70.0%$193.53M$87.69M-7.93150Short Interest ↓NVCTNuvectis Pharma2.7763 of 5 stars$8.24-0.1%$15.67+90.1%+24.6%$192.75MN/A-7.108Positive NewsGap DownOCGNOcugen1.0492 of 5 stars$0.65-2.0%$6.33+876.2%-58.9%$189.46M$4.06M-3.6080Gap DownLFCRLifecore Biomedical1.8219 of 5 stars$5.10-3.6%$8.00+56.9%-3.1%$188.83M$130.86M-9.11690High Trading VolumeGOSSGossamer Bio3.7843 of 5 stars$0.82+2.6%$7.75+844.4%+1.1%$186.46M$114.70M-2.56180Short Interest ↑CRGXCARGO Therapeutics2.8184 of 5 stars$4.03+0.2%$15.00+272.2%-76.8%$185.59MN/A-0.95116High Trading VolumePLXProtalix BioTherapeutics2.4376 of 5 stars$2.34-2.1%$15.00+541.0%+125.1%$182.60M$53.40M-18.00200HUMAHumacyte2.5368 of 5 stars$1.26-6.7%$13.71+988.4%-49.3%$182.50M$1.57M-0.94150Positive NewsZYBTZhengye BiotechnologyN/A$3.85-10.3%N/AN/A$181.59M$189.75M0.00278Gap DownCDTXCidara Therapeutics4.0871 of 5 stars$16.52+0.5%$39.14+136.9%+31.4%$180.94M$1.28M-0.6590Analyst UpgradeShort Interest ↑Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies YMAB Alternatives NVCT Alternatives OCGN Alternatives LFCR Alternatives GOSS Alternatives CRGX Alternatives PLX Alternatives HUMA Alternatives ZYBT Alternatives CDTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMRX Stock Free IMRX Stock Alerts